Bio-Techne Corporation (TECH)

Market Cap	11.61B
Revenue (ttm)	1.12B
Net Income (ttm)	261.82M
Shares Out	157.28M
EPS (ttm)	1.61
PE Ratio	45.66
Forward PE	42.19
Dividend	$0.32 (0.43%)
Ex-Dividend Date	Feb 10, 2023

Volume	603,725
Open	73.05
Previous Close	72.56
Day's Range	72.66 - 74.04
52-Week Range	68.00 - 113.81
Beta	1.24
Analysts	Buy
Price Target	103.14 (+39.66%)
Earnings Date	May 3, 2023

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,000
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH

Financial Performance

In 2022, Bio-Techne's revenue was $1.11 billion, an increase of 18.75% compared to the previous year's $931.03 million. Earnings were $272.05 million, an increase of 93.75%.

Analyst Forecast

According to 20 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $103.14, which is an increase of 39.66% from the latest price.

Price Target

$103.14

(39.66% upside)

Analyst Consensus: Buy